Karyopharm Therapeutics Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
KPTI Nasdaq 2830 www.karyopharm.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Karyopharm Therapeutics Inc.

Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates - Aug 6th, 2026 5:10 pm
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Aug 3rd, 2026 2:05 pm
Karyopharm’s XPORT-EC-042 study fails to meet primary endpoint - Jul 31st, 2026 5:02 am
Why Is KPTI Stock Down 69% After-Hours Today? - Jul 30th, 2026 4:27 pm
Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway - Jul 30th, 2026 2:06 pm
Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer - Jul 30th, 2026 2:05 pm
Madrigal (MDGL) Reports Q2 Loss, Beats Revenue Estimates - Jul 30th, 2026 6:35 am
Karyopharm Therapeutics (KPTI) Soars 5.3%: Is Further Upside Left in the Stock? - Jul 22nd, 2026 5:40 am
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jul 1st, 2026 2:05 pm
Karyopharm Therapeutics (KPTI) Stock Sees Split Analyst Revisions After Phase 3 Trial Update - Jun 25th, 2026 6:06 am
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress - Jun 14th, 2026 7:57 am
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress - Jun 14th, 2026 4:30 am
How The Investment Story Is Evolving For Karyopharm Therapeutics (KPTI) - Jun 7th, 2026 5:06 am
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 - Jun 3rd, 2026 2:15 pm
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026 - Jun 2nd, 2026 8:02 am
Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology - Jun 2nd, 2026 6:59 am
Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation - Jun 1st, 2026 5:30 am
Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference - May 28th, 2026 5:30 am
Wall Street Analysts Think Karyopharm Therapeutics (KPTI) Could Surge 70.46%: Read This Before Placing a Bet - May 27th, 2026 7:55 am
Karyopharm Therapeutics Spotlights Selinexor Milestones, ASCO Data and Cancer Trial Readouts - May 26th, 2026 6:04 am